Chun-fui Lai

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Author Correction: Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells.

Author Correction: Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells.

Journal: The EMBO journal

Published: July 06, 2026

Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells.

Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells.

Journal: The EMBO journal

Published: December 17, 2024

Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.

Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.

Journal: British journal of cancer

Published: February 14, 2024

Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast Cancer.

Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast Cancer.

Journal: Cancer research

Published: January 03, 2024

Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling.

Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling.

Journal: Scientific reports

Published: October 31, 2022

The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.

The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.

Journal: British journal of cancer

Published: July 20, 2022

Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.

Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.

Journal: Oncogene

Published: July 02, 2022

Retraction Note to: FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance.

Retraction Note to: FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance.

Journal: Cell death & disease

Published: May 26, 2021

FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance.

FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance.

Journal: Cell death & disease

Published: June 11, 2018

APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer.

APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer.

Journal: Cell reports

Published: May 14, 2015

Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer.

Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 08, 2015

LRH-1 drives colon cancer cell growth by repressing the expression of the CDKN1A gene in a p53-dependent manner.

LRH-1 drives colon cancer cell growth by repressing the expression of the CDKN1A gene in a p53-dependent manner.

Journal: Nucleic acids research

Published: April 29, 2015

Showing 1-12 of 16

Last Updated: 09/26/2026